Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis

Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory Arthritis

ObjectivesTo compare comorbidities in a cohort of cyclic citrullinated peptide (CCP) antibody positive patients without or prior to onset of inflammatory arthritis (IA) to those in patients with early IA.MethodsBaseline data from two established cohorts were used. The first recruited people at risk...

Full description

Bibliographic Details
Main Authors: Sarah Twigg, Elena Nikiphorou, Jackie L. Nam, Laura Hunt, Kulveer Mankia, Peta Elizabeth Pentony, Jane E. Freeston, Ai Lyn Tan, Paul Emery
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-02-01
Series:Frontiers in Medicine
Subjects:
comorbidities
inflammatory arthritis
rheumatoid arthritis
cyclic citrullinated peptide antibodies
at-risk of arthritis
depression and anxiety disorders
Online Access:http://journal.frontiersin.org/article/10.3389/fmed.2018.00035/full

Internet

http://journal.frontiersin.org/article/10.3389/fmed.2018.00035/full

Similar Items